Articles

MaaT Pharma's Regulatory Update on MaaT013 (Xervyteg®) for GvHD

MaaT Pharma has provided a crucial update on the marketing authorization application for MaaT013 (Xervyteg®), aimed at treating acute Graft-versus-Host Disease. This article explores the implications for investors and pharma teams.

Ascentage Pharma's Olverembatinib Update: Insights from ASCO 2026

Ascentage Pharma has unveiled updated clinical data for Olverembatinib at ASCO 2026, highlighting its potential as a second-line therapy in CML-CP. This article delves into the implications for investors and pharma teams.

OS Therapies Acquires Full IP Rights to OST-HER2 for $8M

OS Therapies has acquired full intellectual property rights to its lead drug OST-HER2 for $8 million, along with two additional cancer assets, enhancing its portfolio in immunology vaccines.

Actinogen's EMA Scientific Advice: A Positive Step for Alzheimer's Program

Actinogen has received positive scientific advice from the EMA, aligning with previous FDA guidance for its Alzheimer's disease program. This development signals potential growth opportunities for investors and stakeholders.

Global Biosimilar Market Analysis: Trends and Challenges

This article analyzes the current trends and challenges in the global biosimilar market, highlighting key implications for stakeholders.

Luxembourg Institute of Science and Technology Joins EuropaBio

The Luxembourg Institute of Science and Technology has joined EuropaBio, marking a significant step in advancing applied biotechnology in Europe. This article explores the implications for the pharmaceutical industry.

Rising Brand-Name Drug Prices in the US: A Global Perspective

This article examines the trend of increasing brand-name drug prices in the US compared to declining prices abroad, highlighting the implications for pharmaceutical companies.

From Promise to Proof: The Shakeup in Today’s Biosimilar Market

This article delves into the evolving landscape of the biosimilar market, highlighting key developments and their implications for stakeholders. Understand the investment opportunities and competitive dynamics shaping the future.

EMA Endorses Novo Nordisk's Wegovy for Weight Loss

The European Medicines Agency has endorsed Novo Nordisk's Wegovy for weight loss, marking a significant milestone in obesity treatment. This analysis explores the implications for investors and pharma teams.

Pfizer's Talzenna Combo: A Game Changer in Prostate Cancer Treatment

Pfizer has made significant strides with its Talzenna combination therapy for castration-sensitive prostate cancer, surpassing Johnson & Johnson. This article delves into the implications of this breakthrough for the pharmaceutical landscape.

Incyte's Strategic Positioning of Monjuvi for First-Line DLBCL

Incyte is strategically positioning Monjuvi for first-line treatment of DLBCL, responding to the competitive landscape of bispecific therapies. This article delves into the implications for pharmaceutical teams and investors.

CVS Restores Coverage for Eli Lilly's Obesity Medications

CVS has reinstated coverage for Eli Lilly's obesity medication Zepbound and introduced a new pill, Foundayo. This decision has significant implications for the pharmaceutical market.

PharmaEssentia's Strategic Move: Eric Vogel Joins to Drive Besremi Expansion

PharmaEssentia has appointed Eric Vogel, a former Incyte executive, to spearhead the expansion of its drug Besremi. This strategic move highlights the company's growth ambitions in the pharmaceutical sector.

EU Panel Endorses Expanded Applications for Cancer Medications

The EMA panel's endorsement for wider uses of cancer drugs marks a significant shift in treatment options, influencing investment strategies and market dynamics. This analysis explores the implications for pharmaceutical stakeholders.

Regulatory Round-Up: Key Updates from EMA - May 2026

This article provides a comprehensive overview of the latest regulatory updates from the EMA as of May 26, 2026, highlighting key implications for the pharmaceutical industry.

Viridian Partners with WuXi Bio for Eye Drug Supply Amid FDA Decision

Viridian has engaged WuXi Bio for the supply of its eye drug, Veligrotug, as it awaits an FDA decision. This partnership highlights significant implications for the pharmaceutical landscape.

EMA's CHMP Endorses Four New Medicines: May Meeting Insights

The EMA's CHMP has backed four new medicines during its May meeting, marking significant advancements in clinical trials. This analysis explores the implications for investors and pharma teams.

Eli Lilly's Legal Victory Over Noom's GLP-1 Claims

Eli Lilly has successfully challenged Noom's claims regarding GLP-1 dosing, impacting the competitive landscape in the pharmaceutical sector. This article explores the implications of this legal victory.

EuropaBio's Stance on Food and Feed Safety Omnibus: Implications for Pharma

This article examines EuropaBio's position on the Food and Feed Safety Omnibus and its potential impact on the pharmaceutical sector.

Tyra's Awareness Day: A New Era for Rare Cancer Advocacy

Tyra's recent awareness day highlights the importance of patient advocacy in rare cancer treatment. This event marks a significant step for pharmaceutical engagement.